Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Bruker Corp Stock Research

BRKR

61.10USD-1.07(-1.72%)Market Closed
Watchlist

Market Summary

USD61.10-1.07
Market Closed
-1.72%

BRKR Stock Price

BRKR RSI Chart

BRKR Valuation

Market Cap

9.0B

Price/Earnings (Trailing)

28.11

Price/Sales (Trailing)

3.3

EV/EBITDA

15.81

Price/Free Cashflow

44.7

BRKR Price/Sales (Trailing)

BRKR Profitability

Operating Margin

51.85%

EBT Margin

16.27%

Return on Equity

26.39%

Return on Assets

8.28%

Free Cashflow Yield

2.24%

BRKR Fundamentals

BRKR Revenue

Revenue (TTM)

2.7B

Revenue Y/Y

15.89%

Revenue Q/Q

-0.5%

BRKR Earnings

Earnings (TTM)

319.1M

Earnings Y/Y

15.35%

Earnings Q/Q

-25.36%

Price Action

52 Week Range

52.2284.84
(Low)(High)

Last 7 days

-0.4%

Last 30 days

-7.3%

Last 90 days

-16.6%

Trailing 12 Months

12.4%

BRKR Financial Health

Current Ratio

2.03

BRKR Investor Care

Dividend Yield

0.33%

Dividend/Share (TTM)

0.2

Buy Backs (1Y)

1.02%

Diluted EPS (TTM)

2.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for BRKR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-11
Munch Mark
sold (taxes)
-105,663
66.96
-1,578
exec vp&pres bruker nano inc.
2023-08-11
Herman Gerald N
sold (taxes)
-61,134
66.96
-913
executive vice president, cfo
2023-08-11
LAUKIEN FRANK H
sold (taxes)
-296,030
66.96
-4,421
president & ceo
2023-08-10
Srega Juergen
acquired
-
-
14,695
president calid
2023-08-10
Busse Falko
acquired
-
-
4,526
president, biospin group
2023-08-10
Prause Burkhard
acquired
-
-
2,371
pres. & ceo, bruker best
2023-08-10
Munch Mark
acquired
-
-
12,410
exec vp&pres bruker nano inc.
2023-08-10
Herman Gerald N
acquired
-
-
12,168
executive vice president, cfo
2023-08-10
LAUKIEN FRANK H
acquired
-
-
38,521
president & ceo
2023-08-09
Munch Mark
sold (taxes)
-140,621
65.68
-2,141
exec vp&pres bruker nano inc.

1–10 of 50

Which funds bought or sold BRKR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
reduced
-59.56
-9,535,360
5,824,010
0.02%
2023-09-20
BARCLAYS PLC
added
228
3,367,000
4,988,000
-%
2023-09-12
Farther Finance Advisors, LLC
added
90.37
11,576
26,325
0.01%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
-334
5,027
-%
2023-09-05
Covenant Partners, LLC
new
-
275,204
275,204
0.10%
2023-09-01
Portside Wealth Group, LLC
new
-
296,198
296,198
0.06%
2023-08-22
COMERICA BANK
new
-
10,000
10,000
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-35.6
-1,009,000
1,537,540
0.01%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
10.43
44,000
1,298,000
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.49
-979,755
9,315,250
0.01%

1–10 of 50

Latest Funds Activity

Are funds buying BRKR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BRKR
No. of Funds

Schedule 13G FIlings of Bruker

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
t. rowe price investment management, inc.
11.1%
16,368,144
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
7.51%
11,045,016
SC 13G/A
Feb 08, 2023
massachusetts financial services co /ma/
5.1%
7,513,039
SC 13G
Jan 31, 2023
blackrock inc.
7.6%
11,118,621
SC 13G/A
Jan 23, 2023
laukien joerg c
5.1%
7,515,769
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
13.7%
20,854,627
SC 13G/A
Feb 09, 2022
vanguard group inc
7.10%
10,765,626
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
blackrock inc.
7.2%
10,844,554
SC 13G

Recent SEC filings of Bruker

View All Filings
Date Filed Form Type Document
Oct 03, 2023
3
Insider Trading
Oct 03, 2023
4
Insider Trading
Sep 29, 2023
SC TO-T/A
SC TO-T/A
Sep 20, 2023
SC TO-T/A
SC TO-T/A
Aug 31, 2023
SC TO-T
SC TO-T
Aug 17, 2023
SC TO-C
SC TO-C
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading

Peers (Alternatives to Bruker)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
192.8B
43.5B
-10.34% -4.46%
33.68
4.43
1.64% -23.14%
32.3B
7.0B
-9.56% -12.76%
28.51
4.62
5.03% -14.68%
23.5B
4.0B
-11.99% -5.07%
26.47
5.95
2.30% 16.37%
21.2B
4.5B
-20.50% -28.48%
-5.05
4.74
-4.92% -21931.58%
9.0B
2.7B
-7.34% 12.40%
28.11
3.3
9.64% 16.50%
MID-CAP
1.5B
551.6M
-23.10% 33.93%
-12.93
2.69
12.73% 21.90%
SMALL-CAP
2.0B
146.1M
-31.29% 34.48%
-6.15
13.44
4.72% -55.19%
1.0B
112.0M
-0.85% 155.15%
-15.26
8.97
0.83% 16.42%
755.0M
189.6M
-23.35% -28.00%
-3.95
3.98
18.74% 17.75%
275.5M
37.3M
-23.67% 12.62%
-2.6
7.38
-9.96% -38.49%
182.7M
114.1M
-2.95% 61.51%
-33.65
1.6
-5.49% -48.58%
138.9M
99.2M
10.56% -67.22%
-2.45
1.4
-26.56% -199.52%
107.8M
80.9M
-7.69% 9.09%
-16.6
1.33
17.20% 77.07%
95.4M
31.5M
-25.45% 59.44%
-0.65
3.03
35.12% -38.47%

Bruker News

Yahoo Finance
Bruker Completes Acquisition of PhenomeX.
Yahoo Finance,
16 hours ago
Marketscreener.com
The Coin Republic
Zacks Investment Research
InvestorsObserver

Returns for BRKR

Cumulative Returns on BRKR

11.7%


10-Year Cumulative Returns

15.9%


7-Year Cumulative Returns

13.2%


5-Year Cumulative Returns

16.5%


3-Year Cumulative Returns

Risks for BRKR

What is the probability of a big loss on BRKR?

73.5%


Probability that Bruker stock will be more than 20% underwater in next one year

37.7%


Probability that Bruker stock will be more than 30% underwater in next one year.

5.4%


Probability that Bruker stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BRKR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bruker was unfortunately bought at previous high price.

Drawdowns

Financials for Bruker

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue3.6%2,7152,6212,5312,5062,4762,4582,4182,3622,2642,1181,9881,9601,9702,0352,0732,0261,9721,9251,8961,8731,842
Cost Of Revenue4.1%1,3131,2621,2251,2241,2211,2211,2081,1811,1441,0921,0481,0371,0411,0621,0771,0551,0311,010996989982
Gross Profit3.1%1,4011,3591,3061,2811,2551,2371,2101,1811,1211,026940923929973995972941915900883860
Operating Expenses3.3%930900873854846817796780752705692670669698694682670649638632626
  S&GA Expenses4.1%650624607596593575561538512479469469479501500487468455445439436
  R&D Expenses4.6%260248236231226223221220216204198188185190188186182177173172171
EBITDA-100.0%-543527500480505497--396321324331347372356335----
EBITDA Margin-100.0%-0.21*0.21*0.20*0.19*0.21*0.21*--0.19*0.16*0.17*0.17*0.17*0.18*0.18*0.17*----
Interest Expenses---24.00---20.00---29.00---16.00---12.00--
Earnings Before Taxes1.9%434427414412392402394380346298226231239256280269252247245233215
EBT Margin-100.0%-0.16*0.16*0.16*0.16*0.16*0.16*0.16*0.15*0.14*0.11*0.12*0.12*0.13*0.14*------
Net Income2.4%31931229727527428227727023820415815816517719720718918418098.0092.00
Net Income Margin-100.0%-0.12*0.12*0.11*0.11*0.11*0.11*0.11*0.10*0.10*0.08*0.08*0.08*0.09*0.10*------
Free Cashflow-100.0%-149145119114176190254312304235169140141140------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets2.5%3,8573,7643,6123,3373,3853,5513,6503,1283,0873,0353,0492,8792,9432,9622,7722,3522,3502,2432,1291,8891,806
  Current Assets2.4%2,1832,1332,1132,0372,0882,2512,4721,9891,9681,9461,9251,8261,9571,9901,7961,4341,4061,3441,3041,2621,182
    Cash Equivalents-3.9%5755986466267268201,072577612700686571750799682300287303326275263
  Inventory6.5%915859800750759740710733730701692696665626577587595542510519509
  Net PPE2.3%523511487422395404406389398384396355336319306278282268271261259
  Goodwill5.8%5585274583823963843403243153133203132952902932822856.002762008.00
  Current Liabilities0.2%1,0511,049914865818881939921955944792683750766646643641633599563532
  Long Term Debt------------------332323225206
    LT Debt, Non Current1.2%1,1231,1091,2011,1371,1711,2051,222718721716842828924915813519494-323--
Shareholder's Equity2.7%1,2311,1991,1149379841,0311,0851,0901,015982974963907925917855870922905817777
  Retained Earnings---1,926---1,660---1,407---1,275---1,103--
  Additional Paid-In Capital---256---238---216---200---177--
Shares Outstanding0.0%147147147147148149151152151152152153154154154154156157157156156
Minority Interest5.4%20.0019.0012.0011.0014.0014.0014.0014.0013.0014.0013.0011.009.009.0010.0010.009.008.009.008.009.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations20.2%342284274242196262282347405395332265235234213210185210240211219
  Share Based Compensation-15.6%22.0026.0028.0028.0027.0021.0017.0017.0017.0017.0016.0010.0010.0010.0010.0013.0013.0012.0011.0011.0011.00
Cashflow From Investing-32.2%-341-258-251-150-141-270-192-172-172-116-192-203-167-232-158-275-292-258-12377.00154
Cashflow From Financing30.4%-159-228-41525.00105139319-159-382-391-16119139750030099.0013378.00-112-278-332
  Dividend Payments-0.7%30.0030.0030.0028.0027.0026.0024.0024.0024.0025.0025.0025.0025.0025.0025.0025.0025.0025.0025.00--
  Buy Backs-33.2%12118126332124822615314014515712373.00123-142285400----

BRKR Income Statement

2023-06-30
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
$ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total revenue$ 681.9$ 588.4$ 1,367.2$ 1,183.4
Total cost of revenue341.4290.2667.0578.9
Gross profit340.5298.2700.2604.5
Operating expenses:    
Selling, general and administrative177.9152.2340.6297.9
Research and development71.059.6140.0116.2
Other charges, net5.412.510.720.0
Total operating expenses254.3224.3491.3434.1
Operating income86.273.9208.9170.4
Interest and other income (expense), net(8.7)(4.3)(24.8)(6.8)
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries77.569.6184.1163.6
Income tax provision19.919.949.851.8
Equity in income of unconsolidated investees, net of tax0.20.00.90.0
Consolidated net income57.849.7135.2111.8
Net income attributable to noncontrolling interests in consolidated subsidiaries0.70.21.60.7
Net income attributable to Bruker Corporation$ 57.1$ 49.5$ 133.6$ 111.1
Net income per common share attributable to Bruker Corporation shareholders:    
Basic$ 0.39$ 0.33$ 0.91$ 0.74
Diluted$ 0.39$ 0.33$ 0.91$ 0.74
Weighted average common shares outstanding:    
Basic146.8149146.8149.7
Diluted147.7149.8147.6150.6
Comprehensive income$ 52.9$ 15.9$ 145.5$ 69.1
Less: Comprehensive income (loss) attributable to noncontrolling interests1.3(0.4)2.6(0.2)
Less: Comprehensive loss attributable to redeemable noncontrolling interest(0.3)(0.5)(0.3)(0.7)
Comprehensive income attributable to Bruker Corporation51.916.8143.270.0
Product    
Total revenue559.6485.81,126.7976.2
Total cost of revenue272.8230.1530.0459.1
Other    
Total revenue122.3102.6240.5207.2
Total cost of revenue$ 68.6$ 60.1$ 137.0$ 119.8

BRKR Balance Sheet

2023-06-30
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 574.8$ 645.5
Accounts receivable, net450.8472.7
Inventories914.6800.1
Assets held for sale0.01.4
Other current assets243.1193.5
Total current assets2,183.32,113.2
Property, plant and equipment, net522.7487.0
Goodwill557.9457.6
Intangible assets, net300.4270.9
Other long-term assets292.7283.1
Total assets3,857.03,611.8
Current liabilities:  
Current portion of long-term debt120.918.7
Accounts payable188.8178.4
Deferred revenue and customer advances397.4370.2
Other current liabilities343.8347.0
Total current liabilities1,050.9914.3
Long-term debt1,122.51,200.5
Other long-term liabilities421.0365.2
Commitments and contingencies (Note 16)
Redeemable noncontrolling interests11.96.1
Shareholders' equity:  
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding0.00.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,498,835 and 175,389,586 shares issued and 146,817,075 and 147,023,144 shares outstanding at June 30, 2023 and December 31, 2022, respectively1.71.7
Treasury stock, at cost, 28,681,760 and 28,366,442 shares at June 30, 2023 and December 31, 2022, respectively(1,107.2)(1,085.0)
Accumulated other comprehensive income, net of tax24.414.8
Other shareholders' equity2,312.32,182.3
Total shareholders' equity attributable to Bruker Corporation1,231.21,113.8
Noncontrolling interests in consolidated subsidiaries19.511.9
Total shareholders' equity1,250.71,125.7
Total liabilities, redeemable noncontrolling interests and shareholders' equity$ 3,857.0$ 3,611.8
Frank H. Laukien
7760
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.